Skip to main content
SpringerLink
Log in

Les agents biologiques et l’hidradénite suppurée (la maladie de Verneuil à l’ère des produits biologiques)

  • Chapter
Hidradénite suppurée

  • 299 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Trent JT, Kerdel FA (2005) Tumor necrosis factor alpha inhibitors for the treatment of dermatologic diseases. Dermatol Nurs 17(2): 97–107

    PubMed  Google Scholar 

  2. Wiseman MC (2004) Hidradenitis suppurativa: a review. Dermatol Ther 17: 50–4

    Article  PubMed  Google Scholar 

  3. Ostlere LS, Langtry JAA, Mortimer PS, Staughton RCD (1999) Hidradenitis suppurativa in Crohn’s disease. Br J Dermatol 125: 384–6

    Article  Google Scholar 

  4. Tsianos EV, Dalekos GN, Tzermias C, Merkouropoulos M, Hatzis J (1995) J Clin Gastroenterol 20(2): 151–3

    Article  PubMed  CAS  Google Scholar 

  5. Katsanos KH, Christodoulou DK, Tsianos EV (2002) Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn’s disease patient. Am J Gastroenterol 97: 2155–6

    Article  PubMed  Google Scholar 

  6. Jemec GBE (2004) Medical treatment of hidradenitis suppurativa. Expert Opin Pharmacother 5(8): 1767–70

    Article  PubMed  CAS  Google Scholar 

  7. Van Assche G, Vermeire S, Rutgeerts P (2005) Medical treatment of inflammatory bowel diseases. Curr Opin Gastroenterol 21(4): 443–7

    PubMed  Google Scholar 

  8. Martinez F, Nos P, Benlloch S et al. (2001) Hidradenitis suppurativa and Crohn’s disease: response to treatment with infliximab. Inflamm Bowel Dis 7(4): 323–6

    Article  PubMed  CAS  Google Scholar 

  9. Lebwohl B, Sapadin AN (2003) Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 49: S275–6

    Article  PubMed  Google Scholar 

  10. Adams DR, Gordon KB, Devenyi AG et al. (2003) Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 139: 1540–2

    Article  PubMed  Google Scholar 

  11. Sullivan TP, Welsh E, Kerdel FA et al. (2003) Infliximab for hidradenitis suppurativa. Br J Dermatol 149: 1046–9

    Article  PubMed  CAS  Google Scholar 

  12. Rosi YL, Lowe L, Kang S (2005) Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn’s disease. J Dermatol Treat 16(1): 58–61

    Article  CAS  Google Scholar 

  13. Mouser JF, Hyams JS (1999) Infliximab: a novel chimeric monoclonal antibody for the treatment of Crohn’s disease. Clin Ther 21: 932–42

    Article  PubMed  CAS  Google Scholar 

  14. Old LJ (1988) Tumor necrosis factor (TNF). Sci Am 258: 59–60

    Article  PubMed  CAS  Google Scholar 

  15. LaDuca JR, Gaspari AA (2001) Targeting tumor necrosis factor alpha. Dermatol Clin 19(4): 617–35

    Article  PubMed  CAS  Google Scholar 

  16. Lebwohl M (2003) Psoriasis. Lancet 361: 1197–204

    Article  PubMed  Google Scholar 

  17. Mease PJ (2002) Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 61(4): 298–304

    Article  PubMed  CAS  Google Scholar 

  18. Provenzano G, Termini A, Le Moli C, Rinaldi F (2003) Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis 62(7): 680–1

    Article  PubMed  CAS  Google Scholar 

  19. Van den Bosch F, Kruithof E, Baeten D et al. (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59(6): 428–33

    Article  PubMed  Google Scholar 

  20. Williams JDL, Griffiths CEM (2002) Cytokine blocking agents in dermatology. Clin Exp Dermatol 27(7): 585–90

    Article  PubMed  CAS  Google Scholar 

  21. Keane J, Gershon S, Wise RP, Schwieterman WD et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15): 1098–104

    Article  PubMed  CAS  Google Scholar 

  22. Tan MH, Gordon M, Lebwohl O et al. (2001) Improvement of pyoderma gangrenosum and psoriasis associated with Crohn’s disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137(7): 930–3

    PubMed  CAS  Google Scholar 

  23. Hanauer SB. (2004) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: overview of randomized clinical studies. Rev Gastroenterol Disord 4(3): S18–S24

    PubMed  Google Scholar 

  24. Baker DE (2004) Adalimumab: human recombinant immunoglobulin G1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord 4(4): 196–210

    PubMed  Google Scholar 

  25. Sandborn WJ (2005) New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease. Rev Gastroenterol Disord 5(1): 10–8

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Dermatologie, University of Miami, 1600 NW 10th Ave Room 2023A RMSB (R250), Miami, Florida, 33136, USA

    Sharon E. Jacob

  2. Service de Dermatologie Cedars Medical Center, Université de Miami, 1400 NW 12th Avenue 6 South, Miami, FL, 33136, USA

    Francisco A. Kerdel

Authors
  1. Sharon E. Jacob
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco A. Kerdel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag France, Paris,

About this chapter

Cite this chapter

Jacob, S.E., Kerdel, F.A. (2008). Les agents biologiques et l’hidradénite suppurée (la maladie de Verneuil à l’ère des produits biologiques). In: Hidradénite suppurée. Springer, Paris. https://doi.org/10.1007/978-2-287-72063-5_20

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-72063-5_20

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-72062-8

  • Online ISBN: 978-2-287-72063-5

Publish with us

Policies and ethics

Search

Navigation